Search Orphan Drug Designations and Approvals
-
Generic Name: | tesevatinib |
---|---|
Date Designated: | 05/26/2021 |
Orphan Designation: | Treatment of autosomal dominant polycystic kidney disease |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Kadmon Corporation 450 East 29th Street New York, New York 10016 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-